

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
10 September 2021 (10.09.2021)



(10) International Publication Number
WO 2021/175823 A1

(51) International Patent Classification:

A61K 38/12 (2006.01) A61K 31/12 (2006.01)

(21) International Application Number:

PCT/EP2021/055131

(22) International Filing Date:

02 March 2021 (02.03.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

20382152.5	02 March 2020 (02.03.2020)	EP
20382192.1	13 March 2020 (13.03.2020)	EP
20382266.3	02 April 2020 (02.04.2020)	EP
20382339.8	27 April 2020 (27.04.2020)	EP
20382815.7	16 September 2020 (16.09.2020)	EP
20382821.5	17 September 2020 (17.09.2020)	EP

(71) Applicant: PHARMA MAR, S.A. [ES/ES]; Polígono Industrial La Mina, Avda. de los Reyes, 1 Colmenar Viejo, 28770 Madrid (ES).

(72) Inventors: IZQUIERDO-USEROS, Nuria; c/o Irsi-CAIXA AIDS Research Institute, Hospital Universitario Germans Trias i Pujol, Crta. del Canyet, s/n, 08916 Barcelona (ES). VERGARA-ALERT, Júlia; c/o IR-TA-CRESA Campus de la Universitat Autònoma de Barcelona, Edifici CRESA s/n, 08193 Barcelona (ES). AVILÉS MARÍN, Pablo; c/o Pharma Mar, S.A. Polígono Industrial La Mina, Avda. de los Reyes, 1 Colmenar Viejo, 28770 Madrid (ES).

(74) Agent: MARKS & CLERK LLP; 62-68 Hills Road, Cambridge CB2 1LA (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,

KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) Title: PLD FOR USE IN COMBINATION IN THE TREATMENT OF CORONAVIRUS

(57) Abstract: The use of PLD with one or more further CoV antiviral agent(s) in the treatment of coronavirus (CoV) infection.




Figure 1

WO 2021/175823 A1